ArticleNano letters2025
Plasmonic Metal-Phenolic Network Nanoprobes for Multiplex Dual-Mode Immunophenotyping.
Article in Nano letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Metal-phenolic networks: a promising strategy for cancer immunotherapy.Journal of translational medicine · 2026Review
- Photothermal Performance of Metal-Phenolic Networks and Its pH-Dependent Coordination Regulation.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Accurate multiplexed immunophenotyping is essential for understanding cellular heterogeneity. Dual-mode detection strategies, such as surface-enhanced Raman scattering (SERS)-fluorescence, offer synergistic advantages and cross-validation to reduce false positives. We present a method for fabricating dual-mode nanoprobes using metal-phenolic networks (MPNs) as functional coatings on hollow plasmonic nanocapsules. Unlike conventional silica shells, MPNs enable the one-step conjugation of biorecognition elements via metal-phenolic coordination, integrating distinct Raman reporters and fluorescently labeled antibodies within a single probe. These plasmonic MPN nanoprobes achieved multiplex detection of the epidermal growth factor receptor and CD44 in cultured cells using SERS and flow cytometry. Application to mixed HER14 and HEK-293 cultures revealed population distributions of ∼63% HER14 and ∼37% HEK-293 as determined by SERS, corroborated by flow cytometry. This work highlights the potential of dual-mode plasmonic MPNs for accurate, scalable immunophenotyping, offering a robust platform for targeted cell imaging and diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.